Prime medicine appoints allan reine, m.d., as chief financial officer

Cambridge, mass., jan. 05, 2024 (globe newswire) -- prime medicine, inc. (nasdaq: prme), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of allan reine, m.d., as the company's chief financial officer, effective january 17, 2024. a seasoned financial executive with over twenty years' experience in the biotechnology industry, dr. reine will be responsible for the company's financing strategy and investor relations, and will oversee all financial operations as prime medicine begins its transition into a clinical company.
PRME Ratings Summary
PRME Quant Ranking